Notice Of Allowance Received From The Us Patent Office On The Use Of Monepantel In Cancer

Feb. 5, 2016 4:11 pm

PharmAust Limited (“PharmAust”) (ASX: PAA) is pleased to report that its key patent “Kinase Inhibitors for the Treatment of Cancer” (14/387,270) has been examined and allowed for issuance in the USA by the United States Trademark And Patent Office. This patent governs the use of the Novartis veterinary drug, monepantel, in the treatment of both human and canine cancers. PharmAust has an “Option to Licence Agreement” with Novartis Animal Health for the use of this intellectual property in the treatment of veterinary cancers.

PharmAust’s Chairman, Dr Roger Aston said: “This is the first of a series of patent applications applied for by the Company which are proceeding towards allowance in the USA and other territories on the use of aminoacetonitriles in cancer. For small biotech companies it is vital to have key controlling intellectual property to enable successful commercialisation.”

For further details about PharmAust please contact:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204

Mr Robert Bishop
Executive Director
Tel: 0417 445 180

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market